Gland Pharma has received Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) indicating closure of the inspection at the Company’s VSEZ Sterile Oncology Facility at Visakhapatnam. The ‘Good Manufacturing Practice (GMP) Inspection’ was conducted by USFDA between July 20, 2023 and July 28, 2023.
Gland Pharma develops, manufactures and markets complex injectables. The company sells its products primarily under a business-to-business model in many countries.
